Journal ArticleDOI
Effects of Propranolol on Azygos Venous Blood Flow and Hepatic and Systemic Hemodynamics in Cirrhosis
Reads0
Chats0
TLDR
The effects of propranolol on blood flow through gastroesophageal collaterals and on systemic and hepatic hemodynamies were investigated and azygos venous blood flow was markedly increased in patients with portal hypertension.About:
This article is published in Hepatology.The article was published on 1984-11-01. It has received 290 citations till now. The article focuses on the topics: Portal venous pressure & Hemodynamics.read more
Citations
More filters
Journal ArticleDOI
The treatment of portal hypertension: A meta-analytic review
Journal ArticleDOI
Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis.
TL;DR: It is suggested that measurement of the HVPG response to pharmacotherapy will provide useful prognostic information on the long-term risk of variceal rebleeding.
Journal ArticleDOI
Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis.
Juan G. Abraldes,Ilaria Tarantino,Juan Turnes,Juan Carlos García-Pagán,Juan Rodés,Jaime Bosch +5 more
TL;DR: In cirrhotic patients receiving pharmacologic treatment for prevention of variceal rebleeding, a decrease in HVPG ≥20% or to ≤12 mm Hg is associated with a marked reduction in the long‐term risk of developing complications of portal hypertension and with improved survival.
Journal ArticleDOI
Prognostic value of early measurements of portal pressure in acute variceal bleeding
Eduardo Moitinho,Angels Escorsell,Juan Carlos Bandi,Joan Manuel Salmerón,Joan–Carles García–Pagán,Juan Rodés,Jaime Bosch +6 more
TL;DR: Early measurement of HVPG in cirrhotic patients during acute variceal bleeding provides useful prognostic information on the evolution of the bleeding episode and long-term survival.
Journal ArticleDOI
Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study.
Pere Ginès,Vicente Arroyo,Enrique Quintero,Ramon Planas,Felipe Bory,J. Cabrera,Antoni Rimola,Josep Maria Viver,Jordi Camps,Wladimiro Jiménez,Ricardo Mastai,Joan Gaya,Joan Rodés +12 more
TL;DR: It is indicated that paracentesis associated with intravenous albumin infusion is a fast, effective, and safe therapy for ascites in patients with cirrhosis.
References
More filters
Journal ArticleDOI
Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine and dopamine.
TL;DR: Modification of the original single isotope radioenzymatic assay of Passon and Peuler permits the direct and simultaneous analysis of norepinephrine, epinephrine and dopamine in plasma samples of 50 μl or less.
Journal ArticleDOI
Measurement of Coronary Sinus Blood Flow by Continuous Thermodilution in Man
TL;DR: The method allowed continuous measurement of flow over a period of several minutes and, for the first time, measurement of rapid changes in myocardial perfusion.
Journal ArticleDOI
Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study
TL;DR: It is concluded that continuous administration of propranolol by mouth is effective in preventing recurrent gastrointestinal bleeding in patients with cirrhosis.
Journal ArticleDOI
Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: Comparison with vasopressin
TL;DR: It is shown that somatostatin effectively reduces hepatic blood flow and portal pressure in patients with cirrhosis and severe portal hypertension, without altering the systemic circulation.
Journal ArticleDOI
Controlled Trial of Propranolol for the Prevention of Recurrent Variceal Hemorrhage in Patients with Cirrhosis
Andrew K. Burroughs,William J. Jenkins,Sheila Sherlock,A.A. Dunk,Robert P. Walt,Tom O. K. Osuafor,Steven Mackie,Robert Dick +7 more
TL;DR: Propranolol may not be indicated for the prophylaxis of variceal rebleeding in patients with cirrhosis and more severe liver disease, and it is advocated that its use be limited at present to controlled clinical trials.